



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

July 15, 2004

David M. Fox
Hogan & Hartson
555 Thirteenth Street, NW
Washington, District of Columbia 20004-1109

Dear Mr. Fox:

Your petition, on behalf of Abbott Laboratories, requesting the Food and Drug Administration to refrain from approving certain applications submitted under section 505(b)(2) of the FDCA that reference Depakote (divalproex sodium delayed-release tablets), was received by this office on 07/15/2004. It was assigned docket number 2004P-0320/CP1 and it was filed on 07/15/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management